Replies to post #246620 on Biotech Values

[rfj1862]

Getting lots of media attention. An analyst on CNBC was just talking about how the weight loss market has really come on in the last year. He expected NOVO with OZEMPIC/WEGOVY going against LLY Mounjaro to become very interesting. He also commented that there was a drug from Viking (VKTX) that could become a player. He didn't mention any other company.

Ah that explains the uptick today

[DewDiligence]

I would turn that around and say that if Mounjaro does not become the biggest-selling drug ever, LLY’s stock is probably overpriced.

[DewDiligence]

NVO’s 1Q23 obesity sales=$1.15B, +124% YoY in constant currency:

https://www.globenewswire.com/news-release/2023/05/04/2661062/0/en/Novo-Nordisk-s-sales-increased-by-27-in-Danish-kroner-and-by-25-at-constant-exchange-rates-to-DKK-53-4-billion-in-the-first-three-months-of-2023.html

1Q23 Wegovy sales would have been even higher if not for constrained manufacturing. In Apr 2023, a second CRO began production of Wegovy.